公开(公告)号：EP2931741A1

公开(公告)日：2015-10-21

申请号：EP13814791.3

申请日：2014-01-15

申请人： Boehringer Ingelheim Vetmedica, Inc.

发明人： IYER, Arun V. ,  JORDAN, Dianna M. Murphy ,  PATTERSON, Abby Rae ,  ROOF, Michael B. ,  VAUGHN, Eric Martin ,  VICTORIA, Joseph Gilbert ,  VISEK, Callie Ann

IPC分类号： C07K14/015 ,  A61K39/23 ,  C12N7/00 ,  C07K16/08 ,  G01N33/569

CPC分类号： A61K39/23 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N7/00 ,  C12N2750/14021 ,  C12N2750/14022 ,  C12N2750/14034 ,  G01N33/6893

摘要： The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.

摘要翻译： 本发明提供新颖的核苷酸序列，蛋白质序列，免疫原性组合物，疫苗和涉及制造和使用感染尤其是家猪的新型猪细小病毒5A（PPV5A）的方法。 组合物和方法提供用于检测所述新病毒的感染，监测野生和家畜和猪群中的病毒序列的遗传变化，以及制备和使用新型疫苗以保护动物免受病毒感染。

公开(公告)号：EP2762163A1

公开(公告)日：2014-08-06

申请号：EP14166489.6

申请日：2007-11-23

申请人： Zoetis P LLC

发明人： Haworth, John David ,  Tucker, Cassius Mcallister

IPC分类号： A61K39/02 ,  A61K39/10 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K39/295

CPC分类号： A61K39/235 ,  A61K39/00 ,  A61K39/0225 ,  A61K39/099 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10071 ,  C12N2710/10334 ,  C12N2750/14034 ,  C12N2750/14071 ,  C12N2750/14334 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18434 ,  C12N2760/18471 ,  C12N2770/20022

摘要： This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

摘要翻译： 本发明涉及一种治疗狗疾病的方法，其包括给狗施用治疗有效量的疫苗，其中该疫苗包含病毒抗原，菌苗或两者，并且其中该疫苗根据本发明的皮下或口服施用 在此提供的时间表。

公开(公告)号：EP2129392B1

公开(公告)日：2013-07-31

申请号：EP07825750.8

申请日：2007-11-23

申请人： Zoetis P LLC

发明人： TUCKER, Cassius, Mcallister ,  HAWORTH, John, David

IPC分类号： A61K39/02 ,  A61K39/175 ,  A61K39/10 ,  A61K39/23 ,  A61K39/12 ,  A61K39/295 ,  A61K39/155

CPC分类号： A61K39/235 ,  A61K39/00 ,  A61K39/0225 ,  A61K39/099 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10071 ,  C12N2710/10334 ,  C12N2750/14034 ,  C12N2750/14071 ,  C12N2750/14334 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18434 ,  C12N2760/18471 ,  C12N2770/20022

公开(公告)号：EP2467484A4

公开(公告)日：2013-06-12

申请号：EP10815817

申请日：2010-08-23

申请人： VIRGINIA TECH INTELL PROP

发明人： MENG XIANG-JIN ,  HUANG YAOWEI

IPC分类号： C12N15/34 ,  A61K39/12 ,  C12N15/63 ,  C12Q1/68 ,  G01N33/569

CPC分类号： G01N33/56983 ,  A61K39/12 ,  A61K2039/552 ,  C07K14/005 ,  C07K16/081 ,  C12N7/00 ,  C12N2750/00021 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/14034 ,  C12Q1/701 ,  G01N2333/01 ,  G01N2333/085 ,  G01N2469/20

摘要： The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1 a-VA, PTTV1 b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies.

公开(公告)号：EP2331117A4

公开(公告)日：2013-01-23

申请号：EP09815049

申请日：2009-09-15

申请人： UNIV OKLAHOMA STATE

发明人： KAPIL SANJAY ,  COOPER EMILY

IPC分类号： A61K39/23 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  C12Q1/70 ,  G01N33/569

CPC分类号： A61K39/23 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2750/14022 ,  C12N2750/14032 ,  C12N2750/14034 ,  C12N2750/14043 ,  C12N2750/14051 ,  C12N2750/14071 ,  C12N2750/14334 ,  C12Q1/701 ,  G01N33/56983 ,  G01N2333/015

公开(公告)号：EP1931364B1

公开(公告)日：2010-07-21

申请号：EP06806096.1

申请日：2006-10-06

申请人： Nestec S.A.

发明人： KNORR, Ruth ,  CAVADINI, Christoph ,  BENYACOUB, Jalil ,  SATYARAJ, Ebenezer

IPC分类号： A61K35/74 ,  A23K1/00

CPC分类号： C12R1/01 ,  A23K10/18 ,  A23K20/168 ,  A23K20/184 ,  A23K50/40 ,  A23K50/48 ,  A23L33/135 ,  A61K31/5685 ,  A61K35/744 ,  A61K39/12 ,  A61K39/125 ,  A61K39/23 ,  A61K39/245 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2750/14034 ,  C12N2770/16034 ,  C12R1/46

公开(公告)号：EP2164333A2

公开(公告)日：2010-03-24

申请号：EP08754373.2

申请日：2008-05-13

申请人： Nestec S.A.

发明人： KNORR, Ruth ,  CAVADINI, Christoph ,  BENYACOUB, Jalil ,  SATYARAJ, Ebenezer

IPC分类号： A01N63/00 ,  A61K39/02

CPC分类号： A61K39/245 ,  A23K10/18 ,  A23K50/48 ,  A61K39/12 ,  A61K39/125 ,  A61K39/23 ,  A61K2039/5254 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N2710/16034 ,  C12N2750/14034 ,  C12N2770/16034

摘要： Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and/or preventing or treating conjunctivitis in animals. The compositions contain effective amounts of probiotic Enterococcus bacteria and the methods involve administering such compositions to animals alone, in supplements, or in food compositions in amounts suitable for the intended purpose. In certain embodiments, the probiotic is Enterococcus faecium strain NCIMB 10415 (SF68) and the animal is a feline.

公开(公告)号：EP2150624A1

公开(公告)日：2010-02-10

申请号：EP08767903.1

申请日：2008-05-28

申请人： Wyeth LLC

发明人： WU, Stephen, Qitu ,  GILL, Michael, A. ,  CHU, Hsien-Jue

IPC分类号： C12Q1/68 ,  C12Q1/70 ,  A61K39/275

CPC分类号： A61K39/205 ,  A61K39/0225 ,  A61K39/12 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N15/86 ,  C12N2710/10334 ,  C12N2710/24143 ,  C12N2750/14034 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20134 ,  C12N2770/20034

摘要： The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention.

公开(公告)号：EP1592444B1

公开(公告)日：2008-05-14

申请号：EP04702384.1

申请日：2004-01-15

申请人： Pfizer Products Inc.

发明人： DOMINOWSKI, Paul, Joseph ,  FRANTZ, Joseph, Claude ,  KREBS, Richard, Lee ,  SHIELDS, Shelly, Lynn ,  SORENSEN, Robert, Greg

IPC分类号： A61K39/10 ,  A61K39/295 ,  A61K39/39

CPC分类号： A61K39/0225 ,  A61K39/099 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K39/235 ,  A61K2039/521 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/55577 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2750/14034 ,  C12N2760/18034 ,  C12N2760/18434

摘要： This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.

公开(公告)号：EP1370668B1

公开(公告)日：2006-02-22

申请号：EP02732485.4

申请日：2002-03-07

申请人： Akzo Nobel N.V.

发明人： SPIBEY, Norman

IPC分类号： C12N15/86

CPC分类号： A61K39/275 ,  A61K39/12 ,  A61K39/125 ,  A61K39/21 ,  A61K39/23 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/552 ,  C12N15/86 ,  C12N2710/24034 ,  C12N2710/24043 ,  C12N2740/13034 ,  C12N2750/14034 ,  C12N2770/16034

摘要： The present invention is directed to the use of a live, recombinant leporipox virus comprising exogenous DNA which is operably linked to at least one expression control element and which is incorporated in a non-essential region of the virus genome, in the manufacture of a vector vaccine for the treatment and/or prophylaxis of infectious diseases in non-lepori species. The invention furthermore relates to a live, recombinant leporipox virus comprising exogenous DNA operably linked to at least one expression control element and incorporated in a non-essential region of the virus genome characterized in that said exogenous DNA encodes at least one antigen of a non-lepori pathogen. Due to its restricted host-range the recombinant leporipox virus is non-pathogenic in non-susceptible hosts such as non-lepori vertebrates. Vaccination with said recombinant leporipox virus induced an antigenic or immunogenic response in the vaccinated non-lepori host even though productive replication of the virus was not observed in the host.